Peter Shrader
Overview
Explore the profile of Peter Shrader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
5434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shoji S, Shah N, Shrader P, Thomas L, Arnold J, Dhalwani N, et al.
Am J Prev Cardiol
. 2025 Jan;
21:100921.
PMID: 39876978
Objective: Lowering lipid to reach guideline-indicated goals significantly reduces cardiovascular outcomes in very-high-risk (VHR) patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (DM2). How well VHR patients currently...
2.
Duran J, Shrader P, Hong C, Haddad F, Santana E, Cauwenberghs N, et al.
Circ Cardiovasc Imaging
. 2025 Jan;
18(2):e017380.
PMID: 39801490
Background: Patients with abnormal (positive) exercise electrocardiography, but normal stress echocardiography (+ECG/-Echo), have an increased risk of adverse cardiovascular events compared with patients with a normal (negative) ECG and a...
3.
Jason M, Marzec L, Piccini J, Shrader P, Pieper K, Blanco R, et al.
Int J Cardiol
. 2024 Dec;
421():132912.
PMID: 39708904
Background: Decisions about stroke prevention strategies in atrial fibrillation (AF) typically balance thromboembolism reduction against increased bleeding from oral anticoagulation therapy (OAC). When determining eligibility for OAC, guidelines recommend calculation...
4.
Andreae A, Black-Maier E, Arps K, Kobe E, Johnson T, Shrader P, et al.
Heart Rhythm
. 2024 Jul;
22(2):394-402.
PMID: 39053752
Background: Implantable cardioverter-defibrillator (ICD) shocks are a common complication after left ventricular assist device (LVAD) implantation; however, data on their frequency and causes are limited. Objective: The purpose of this...
5.
Navar A, Shah N, Shrader P, Thomas L, Ahmad Z, Allred C, et al.
Am Heart J
. 2024 Jul;
279:107-117.
PMID: 38972336
Background: Reflecting clinical trial data showing improved outcomes with lower LDL-C levels, guidelines across the globe are increasingly recommending a goal of LDL-C <55 mg/dL in persons with atherosclerotic cardiovascular...
6.
Cholera R, Anderson D, Chung R, Genova J, Shrader P, Bleser W, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2327264.
PMID: 37540515
Importance: Despite momentum for pediatric value-based payment models, little is known about tailoring design elements to account for the unique needs and utilization patterns of children and young adults. Objective:...
7.
Carlisle M, Shrader P, Fudim M, Pieper K, Blanco R, Fonarow G, et al.
Heart Rhythm O2
. 2023 Jan;
3(6Part A):621-628.
PMID: 36589908
Background: Oral anticoagulation (OAC) reduces the risk of thromboembolic events in patients with atrial fibrillation (AF); however, thromboembolism (TE) still can occur despite OAC. Factors associated with residual risk for...
8.
Ringold S, Dennos A, Kimura Y, Beukelman T, Shrader P, Phillips T, et al.
Arthritis Care Res (Hoboken)
. 2022 Aug;
75(4):715-723.
PMID: 35921198
Objective: Children with well-controlled juvenile idiopathic arthritis (JIA) frequently experience flares after medication discontinuation, but the outcomes of these flares have not been well described. The objective of this study...
9.
Shiff N, Shrader P, Correll C, Dennos A, Phillips T, Beukelman T
Rheumatology (Oxford)
. 2022 Jun;
62(2):804-814.
PMID: 35703945
Objective: To describe 2-year trajectories of the clinical Juvenile Arthritis Disease Activity Score, 10 joints (cJADAS10) and associated baseline characteristics in patients with JIA. Methods: JIA patients in the Childhood...
10.
Verstegen R, Shrader P, Balevic S, Beukelman T, Correll C, Dennos A, et al.
Arthritis Care Res (Hoboken)
. 2022 Jan;
75(2):410-422.
PMID: 35040593
Objective: To determine the dose-response relationship of tumor necrosis factor (TNF) inhibition in the treatment of juvenile idiopathic arthritis (JIA). Methods: Participants of the Childhood Arthritis and Rheumatology Research Alliance...